3 ms·
I would say they’re following Zymergen’s business model… except that model turned out to be “defrauding the investors.”
by john_yaya 5y ago
I would say they’re following Zymergen’s business model… except that model turned out to be “defrauding the investors.”
- refurb 5y agoAnother comment referenced this article which seems to suggest the valuation is based mostly on "promise". https://www.technologyreview.com/2021/08/24/1032308/is-ginkgos-synthetic-biology-story-worth-15-billion/amp/ https://www.technologyreview.com/2021/08/24/1032308/is-ginkg...